M&A analysis: Merck and Gilead splash the cash
The groups spend big on Terns and Arcellx.
ASH 2025 preview – toxicity worries hit BeOne’s sonrotoclax
The project has priority review, but deaths could raise eyebrows.
The groups spend big on Terns and Arcellx.
The project has priority review, but deaths could raise eyebrows.
